Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1995-11-28
1998-06-02
Achutamurthy, Ponnathapura
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
5303898, 4241931, 4241751, 4242361, 4242611, 42419611, 42419711, C07K 1600, A61K 39385, A61K 39395
Patent
active
057601844
ABSTRACT:
Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo are disclosed. Methods of preparing the hapten-carrier conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.
REFERENCES:
patent: 3888886 (1975-06-01), Leute et al.
patent: 4045420 (1977-08-01), Soffer et al.
patent: 4123431 (1978-10-01), Soffer et al.
patent: 4197237 (1980-04-01), Leute et al.
patent: 4375414 (1983-03-01), Strahilevitz
patent: 4620977 (1986-11-01), Strahilevitz
patent: 4666837 (1987-05-01), Harford et al.
patent: 4791067 (1988-12-01), Sheiman et al.
patent: 4813924 (1989-03-01), Strahilevitz
patent: 4834973 (1989-05-01), Strahilevitz
patent: 5019384 (1991-05-01), Gefter et al.
patent: 5037645 (1991-08-01), Strahilevitz
patent: 5256409 (1993-10-01), Blincko
patent: 5268276 (1993-12-01), Holmgren et al.
patent: 5283066 (1994-02-01), Liu et al.
Carroll et al., (1994) Pharm. News 1:11-16.
Bonese et al., (1974)Nature 252:708-710.
Bagasra et al., (1992) Immunopharmacol. 23:173-179.
Gallacher (1994) Immunopharm. 27:79-81.
Killian et al., (1978) Pharmacol. Biochem. Behavior 9:347-352.
Pentel et al., (1991) Drug Met. Dispositions 19:24-28.
Landary et al., (1993) Science 259:1899-1901.
McKenzie et al., The Journal of Immunology., vol. 133., No. 4., pp. 1818-1824, Oct. 1984.
Curreru et al. (1993) Society for Neuroscience 754.4 (Abstract).
Chuong et al. (1977) Annales Pharmaceutiques Francaises 35:257-264 (Translation).
Kovalev et al. (1979 Khim. Farm. (USSR) pp. 615-618 with translation.
Ambre et al. (1991) Journal of Analytical Toxicology 15:17-20.
Holmgren et al. (1994) Am. J. Trop. Med. Hyg. pp. 42-54.
Inaba, "Cocaine: Pharmacokinetics and biotransformation in man", SFBS Symposium on Frontiers in Cocaine Research, Quebec, Canada, Jun. 15, 1988, pp. 1154-1157.
Jatlow (1988) The Yale Journal of Biology and Medicine 61:105-113.
Kantack et al. (1992) Pharm. Biochem. and Behavior 41:415-423.
Manganaro (1994) Int. Arch. Immunol. 103:223-233.
Stok et al. (1994) Vaccine 12:521-526.
Slos (1994) Protein Expression and Purification 5:518-526.
Witkin (1994) Neurosci. and Biobehav. Reviews 18:121-142.
Jones-Witters and Witters, Drugs and Society-A Biological Perspective, Wadsworth Health Sciences Division, 1983, Wadsworth, Inc., Belmont, California 94002, pp. 142-147.
Witkin (1994) Neurosci. and Biobehav. Reviews 18121-142.
We et al. (1994) Vaccine 12215-222.
Wainer et al. (1972) Science 176:1143-1145.
Wainer et al. (19720 Science 178:647-648.
Spector et al. (1970) Science 168:1347-1348.
Wainer et al. (1973) The Journal of Immunology 110:667-673.
Van Vunakis et al. (1972) The Journal of Pharmacology and Experimental Therapeutics 180:514-521.
Spector (1971) The Journal of Pharmacology and Experimental Therapeutics 178:253-258.
Castro et al. (1980) Eur. J. Biochem 104: 331-340.
Castro et al. (1975) Biochemical and Biophysical Research Communications 67:583-589.
Matsushita et al. (1974) Biochemical and Biophysical Research Communications 57:1006-1010.
Castro et al. (1985) Biochemical Archives 1:173-183.
Castro et al. (1986) Research Communications in Chemical Pathology and Pharmacology 51:393-404.
Decato et al. (1977) Journal of Immunological Methods 18:201-213.
Killian et al. (1978) Pharmacology Biochemistry & Behavior 9:347-352.
Berkowitz (1972) Science 178:1290-1292.
Berkowitz et al. (1975) Life Sciences 15:1017-1028.
Zimmermann et al. (1976) Proc. West. Pharmacol. Soc. 19:260-265.
Spector et al. (1973) Pharmacological Reviews 25:281-291.
Spector (1976) Biochemical Pharmacology 25:2427-2428.
Lomax et al. (1973) Proc. West. Pharmacol. Soc. 16:252-256.
Wainer et al. (1973) Nature 241:537-538.
Miller et al. (1974) Proc. West. Pharmacol. Soc. 17:69-72.
Herndon (1975) Life Sciences 17:151-158.
Schmidt et al. (1971) The Journal of Clinical Investigation 50:866-871.
Colburn (1980) Drug Method Rev. 11:223-262.
Pentel et al. (1991) Drug Meth. & Disp. 19:24-28.
Kovalev et al. (1980) Khim. Pharm. pp. 200-204.
Briner Thomas J.
Exley Mark A.
Fox Barbara S.
Gefter Malcolm L.
Greenstein Julia L.
Achutamurthy Ponnathapura
ImmuLogic, Inc.
Ponnaluri Padmashri
LandOfFree
Hapten-carrier conjugates for use in drug-abuse therapy and meth does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hapten-carrier conjugates for use in drug-abuse therapy and meth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hapten-carrier conjugates for use in drug-abuse therapy and meth will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1461126